After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
The startup nabbed a $29.3 billion valuation in a $2.3 billion funding round Thursday, minting its four 20-something founders as billionaires.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback